Sign In
Buy VXRT
$0.519
-0.0111 (-2.09%)
At Close: Jun 23, 2026
Vaxart’s S-Only COVID-19 Vaccine Candidate Produces Strong-Cross Reactive Mucosal and Systemic Immune Responses in Non-Human Primates
01:30pm, Thursday, 24'th Feb 2022 GlobeNewswire Inc.
Newly published data demonstrates substantial cross-reactivity against multiple variants of COVID-19
These 2 Stocks Carry a Lot of Risk, but Their Upside Is Huge
11:15am, Wednesday, 23'rd Feb 2022 The Motley Fool
A big opportunity may be ahead for both of these companies.
These 2 Stocks Carry a Lot of Risk, but Their Upside Is Huge
06:15am, Wednesday, 23'rd Feb 2022
A big opportunity may be ahead for both of these companies.
Earnings Preview: VAXART, INC. (VXRT) Q4 Earnings Expected to Decline
08:02pm, Thursday, 17'th Feb 2022 Zacks Investment Research
VAXART, INC. (VXRT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: VAXART, INC. (VXRT) Q4 Earnings Expected to Decline
04:11pm, Thursday, 17'th Feb 2022
VAXART, INC. (VXRT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.
This Reopening Stock Has A Better 1-Year Return Than Moderna, Pfizer, BioNTech, Novavax And Vaxart
03:07pm, Thursday, 17'th Feb 2022 Benzinga
Macy's Inc (NYSE: M) retail stores have something for everyone in the family, and over the past year, has returned unmistakable gains for bullish traders and investors.
Since February 2021, Macy’s s
This Reopening Stock Has A Better 1-Year Return Than Moderna, Pfizer, BioNTech, Novavax And Vaxart
03:07pm, Thursday, 17'th Feb 2022 Benzinga
Macy''s Inc (NYSE: M ) retail stores have something for everyone in the family, and over the past year, has returned unmistakable gains for bullish traders and investors. Since February 2021, Macy’s stock’s one-year return has outperformed several of the world’s most popular vaccine stocks: Moderna Inc (NASDAQ: MRNA ), Pfizer Inc. (NYSE: PFE ), BioNTech SE - ADR (NASDAQ: BNTX ), Novavax, Inc. (NASDAQ: … Full story available on Benzinga.com
ImmunoGen (IMGN) Up on Licensing Deal With Lilly Worth $1.7 B
03:58pm, Wednesday, 16'th Feb 2022 Zacks Investment Research
ImmunoGen (IMGN) inks a licensing agreement with Eli Lilly, granting the latter rights to develop and commercialize ADCs directed toward targets selected by Lilly. Stock up.
Corcept's (CORT) Q4 Earnings Beat Estimates, Revenues Miss
02:54pm, Wednesday, 16'th Feb 2022 Zacks Investment Research
Corcept's (CORT) earnings beat estimates in the fourth quarter of 2021 while revenues miss the same.
Corcept Therapeutics (CORT) Q4 Earnings Beat Estimates
10:55pm, Tuesday, 15'th Feb 2022 Zacks Investment Research
Corcept (CORT) delivered earnings and revenue surprises of 18.18% and 2.32%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Brookdale Senior Living (BKD) Reports Q4 Loss, Lags Revenue Estimates
10:55pm, Monday, 14'th Feb 2022 Zacks Investment Research
Brookdale (BKD) delivered earnings and revenue surprises of -10% and 0.48%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Is Vaxart Stock a Buy Now?
04:23pm, Friday, 11'th Feb 2022 The Motley Fool
This vaccine company has a lot of catching up to do.
Is Vaxart Stock a Buy Now?
04:23pm, Friday, 11'th Feb 2022 The Motley Fool
This vaccine company has a lot of catching up to do.
Is Vaxart Stock a Buy Now?
11:23am, Friday, 11'th Feb 2022
This vaccine company has a lot of catching up to do.
All You Need to Know About VAXART, INC. (VXRT) Rating Upgrade to Buy
05:00pm, Monday, 07'th Feb 2022 Zacks Investment Research
VAXART, INC. (VXRT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
